APA (7th ed.) Citation

G, H., S, T., P, L., RI, B., T, B., J, B., . . . TS, C. (2025). Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): A randomised, controlled, double-blind, phase 3 trial. The Lancet. Infectious diseases, 25(7), 813. https://doi.org/10.1016/S1473-3099(24)00804-1

Chicago Style (17th ed.) Citation

G, Haidar, et al. "Efficacy and Safety of Sipavibart for Prevention of COVID-19 in Individuals Who Are Immunocompromised (SUPERNOVA): A Randomised, Controlled, Double-blind, Phase 3 Trial." The Lancet. Infectious Diseases 25, no. 7 (2025): 813. https://doi.org/10.1016/S1473-3099(24)00804-1.

MLA (9th ed.) Citation

G, Haidar, et al. "Efficacy and Safety of Sipavibart for Prevention of COVID-19 in Individuals Who Are Immunocompromised (SUPERNOVA): A Randomised, Controlled, Double-blind, Phase 3 Trial." The Lancet. Infectious Diseases, vol. 25, no. 7, 2025, p. 813, https://doi.org/10.1016/S1473-3099(24)00804-1.